Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.49 |
| ▸ | MITF | O75030 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 12/20 | 0.48 |
| ▸ | MEN1 | O00255 | 9/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.48 |
| ▸ | HTT | P42858 | 6/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1057905 | 1.00 | POLB (0.49) | POLBMITFMAPTMEN1KMT2A | |
| SCHEMBL1056357 | 0.84 | MAPT (0.49) | POLBMAPTMEN1KMT2AHTT | |
| SCHEMBL1056358 | 0.84 | MAPT (0.49) | POLBMAPTMEN1KMT2AHTT | |
| SCHEMBL1054711 | 0.82 | MAPT (0.47) | POLBMAPTMEN1KMT2AHTT | |
| SCHEMBL1054710 | 0.82 | MAPT (0.47) | POLBMAPTMEN1KMT2AHTT | |
| SCHEMBL1059298 | 0.81 | GSK3B (0.49) | POLBMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL1059295 | 0.81 | GSK3B (0.49) | POLBMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL1055993 | 0.81 | KDM4E (0.47) | POLBMAPTMEN1KMT2AHTT | |
| SCHEMBL1055994 | 0.81 | KDM4E (0.47) | POLBMAPTMEN1KMT2AHTT | |
| SCHEMBL1052859 | 0.78 | GAA (0.51) | POLBMAPTMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204251-A1 | MOLECULAR TARGET OF NEUROTOXICITY | EXONHIT THERAPEUTICS SA (FR) | 2010-08-12 | — | — | US | claimed |
| EP-1982704-B1 | New molecular target of neurotoxicity | EXONHIT THERAPEUTICS SA (FR) | 2010-08-04 | — | — | EP | claimed |
| US-20060241062-A1 | Method involving pde4, compositions, and the screening thereof, for the treatment of degenerative ocular pathologies | EXONHIT THERAPEUTICS SA (FR) | 2006-10-26 | — | — | US | claimed |
| US-20060142326-A1 | Use of pyrazolopyridines for the treatment of cognitive deficits | DIAXONHIT (FR) | 2006-06-29 | — | — | US | claimed |
| US-20050043319-A1 | Detecting neuronal stress via monitoring in vitro expression of phosphodiesterases; diagnosis, prevention and treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; drug screening | EXONHIT THERAPEUTICS SA (FR) | 2005-02-24 | — | — | US | claimed |
| US-20040219552-A1 | Novel molecular target for neurotoxicity | EXONHIT THERAPEUTICS SA (FR) | 2004-11-04 | — | — | US | claimed |
| US-20120202846-A1 | MOLECULAR TARGET OF NEUROTOXICITY | EXONHIT THERAPEUTICS SA (FR) | 2012-08-09 | — | — | US | disclosed |
| US-7872015-B2 | Methods involving PDE4, compositions, and the screening thereof, for the treatment of degenerative ocular pathologies | EXONHIT THERAPEUTICS SA (FR) | 2011-01-18 | — | — | US | disclosed |
| US-20100204251-A1 | MOLECULAR TARGET OF NEUROTOXICITY | EXONHIT THERAPEUTICS SA (FR) | 2010-08-12 | — | — | US | disclosed |
| EP-1982704-B1 | New molecular target of neurotoxicity | EXONHIT THERAPEUTICS SA (FR) | 2010-08-04 | — | — | EP | disclosed |
| US-20090317842-A1 | Methods and Tools for The Therapy of Neurodegenerative Pathologies | EXONHIT THERAPEUTICS SA (FR) | 2009-12-24 | — | — | US | disclosed |
| EP-1417349-B1 | NOVEL MOLECULAR TARGET FOR NEUROTOXICITY | EXONHIT THERAPEUTICS SA (FR) | 2008-11-19 | — | — | EP | disclosed |
| EP-1982704-A2 | New molecular target of neurotoxicity | Exonhit Therapeutics SA (FR) | 2008-10-22 | — | — | EP | disclosed |
| US-20060241062-A1 | Method involving pde4, compositions, and the screening thereof, for the treatment of degenerative ocular pathologies | EXONHIT THERAPEUTICS SA (FR) | 2006-10-26 | — | — | US | disclosed |
| US-20060142326-A1 | Use of pyrazolopyridines for the treatment of cognitive deficits | DIAXONHIT (FR) | 2006-06-29 | — | — | US | disclosed |
| US-20040219552-A1 | Novel molecular target for neurotoxicity | EXONHIT THERAPEUTICS SA (FR) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043319-A1 | Detecting neuronal stress via monitoring in vitro expression of phosphodiesterases; diagnosis, prevention and treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; drug screening | PDE4B, PDE4A, PDE4D | POLB 152/4885MITF 2876/4885MAPT 457/4885 |
| US-20090317842-A1 | Methods and Tools for The Therapy of Neurodegenerative Pathologies | SNCA, BACE1, BDNF | POLB 605/4885MITF 4578/4885MAPT 20/4885 |
| US-20120202846-A1 | MOLECULAR TARGET OF NEUROTOXICITY | PDE4B, TDP2, PDE4A | POLB 78/4885MITF 2237/4885MAPT 499/4885 |
| US-20060241062-A1 | Method involving pde4, compositions, and the screening thereof, for the treatment of degenerative ocular pathologies | PDE4B, PDE4A, GABRA4 | POLB 281/4885MITF 1968/4885MAPT 1974/4885 |
| US-20060142326-A1 | Use of pyrazolopyridines for the treatment of cognitive deficits | QDPR, ACHE, GRN | POLB 3727/4885MITF 3593/4885MAPT 11/4885 |
| US-20100204251-A1 | MOLECULAR TARGET OF NEUROTOXICITY | PDE4B, TDP2, PDE4A | POLB 78/4885MITF 2237/4885MAPT 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.